ESTRO 2021 | CyberKnife radiotherapy lessens toxicity in PACE-B

Alison Tree, BSc, MBBS, FRCR, MD(res), The Royal Marsden NHS Foundation Trust, London, UK, explores how the PACE-B trial (NCT01584258) saw unexpected benefits in using a CyberKnife machine compared to a conventional radiotherapy machine to deliver treatment for localized prostate cancer. Dr Tree recommends further research into why lower toxicity was seen in patients who received hypofractionated stereotactic body radiotherapy (SBRT) via a CyberKnife machine compared to those who received SBRT via a normal radiotherapy machine. This interview took place at the European Society for Radiotherapy and Oncology (ESTRO) 2021.